Lisata Therapeutics Inc (LTS:0HS8)
$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Caladrius Biosciences Inc at LD Micro Virtual Zooming Conference Transcript

Jul 29, 2021 / 05:00PM GMT
Release Date Price: $20.69 (+0.73%)
Christopher Lahiji
LD Micro, Inc. - Founder & President

It is truly a privilege to introduce our next presenter. Based out of Basking Ridge, New Jersey, Caladrius Biosciences, ticker CLBS on the NASDAQ, is dedicated to the development of cellular therapies designed to reverse disease. The company's current product candidates include CLBS16, which is for the treatment of coronary microvascular dysfunction, or CMD; CLBS12 which targets Buerger's Disease in the U.S.; as well as CLBS201 designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

Caladrius has participated in our conferences over the years, and I have the utmost pleasure of spending a day with management, mostly Second Bay Area traffic and discussing my fast food eating habits. The only thing I really concluded from the trip is that jack-in-the-box is probably not good for your overall health. And the management team here takes incredible pride in what they do each and every day.

Joining us on the call today, it is my privilege and pleasure to welcome the President and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot